Delivering more for human health and beyond
Medlab Clinical (ASX: MDC) is an Australian publicly listed biotechnology company with a global market opportunity. Our team of scientists, researchers and doctors are dedicated to building products that are scientifically optimised for a better life, specialising in oncology and enhanced drug delivery.
Medlab has a portfolio of novel cannabinoid-based assets enhanced by our leading drug delivery platform. Our lead drug candidate, NanaBis™, is an opioid alternative for cancer-induced pain management, with company-making potential and a global market opportunity.
Core to our value proposition is NanoCelle®, our patented sub-micron drug delivery platform that vastly improves drug solubility issues and enables faster absorption and metabolism of active ingredients. NanoCelle® underpins our growth strategy by offering near-term partnering opportunities whilst enhancing our pharma portfolio.
Investment Highlights
- Patented NanoCelle® drug delivery platform with value creation optionality, enhancing our product portfolio whilst offering near term partnering opportunities
- World-class Board, management and scientific consulting team with strong experience bringing novel therapeutics to market
- Scientifically optimised portfolio of cannabinoid therapeutics addressing a global unmet need in oncology areas including pain management
- Lead candidate NanaBis™ Phase I/II primary and secondary endpoints met in bone cancer patients, replicated in a real-world observational study. Stage III commencing in near-term with robust and clear drug pathway in US, EU and Australia
- NanaBis™ proof of concept established and early revenue being generated via Special Access Scheme
Have an investor relationship question, you can book a meeting with our CEO, Dr Sean Hall
Sign up for Investor Updates
Stay up-to-date with the latest investor news, presentations and videos from Medlab sent directly to your email address.
Latest Investor News
Small Caps interview of CEO Sean Hall
Small Caps interviews the CEO of Medlab, Sean Hall about the future of NanoCelle® drug delivery technology and pharmaceutical portfolio
2021-04-22
Medlab mixes reality with Microsoft
Read the three featured stories from Microsoft about Medlab's adoption of mixed reality solutions including HoloLens 2 head-mounted devices with Dynamics 365 Remote Assist, to help combat the pandemic by improving time to market and guaranteeing crucial business progression.
2021-04-14
NanaBis demonstrates continued improvement in pain scores
The first cohort of Observational Study patients completing 12-month treatment with NanaBis™ demonstrated continued improvement in pain scores.
2021-04-12
Medlab to be granted European patent for NanoCelle® drug delivery platform
European Patent Office issues Notice of Intention to grant Medlab Clinical patent for NanoCelle® drug delivery platform
2021-04-07
Novartis’ Managing Director of Oncology (ANZ/NZ) joins Medlab Clinical board
Medlab Clinical appoints Novartis' Managing Director of Oncology for Australia and New Zealand as Non-Executive Director.
2021-03-23
Medlab Clinical raises $15 million and Leading Executive Joins Board
Medlab Clinical successfully raised $15 million to help fund its upcoming Phase III clinical trial and has extended its board expertise with the appointment of leading pharmaceutical executive Mrs Cheryl Maley.
2021-03-19
Medlab Clinical looks for $15 million equity injection
Medlab clinical looks to raise $15 million to fund its Phase III trial. Read more here.
2021-03-17
Medlab Clinical partners with Arrotex
Medlab Clinical partners with Arrotex to accelerate NanoCBD availability in Australian pharmacies
2021-02-18
Medlab to confirm NanaBis’ potential as non-opioid analgesic in phase III trial
Read the write up from Small Caps about Medlab's non-opioid pain treatment
2021-01-27
Ausbiz interview of CEO Sean Hall
Ausbiz interviews the CEO of Medlab, Sean Hall about the future of Medlab
2021-01-27
IND Acceptance Investor Update
NanaBis has been granted IND status by the US FDA, allowing Medlab to initiate its pivotal Phase III study at US sites
2021-01-19
Switzer Investor Day
4th Small and Micro-Cap Virtual Investor Day
2020-12-02
Ausbiz interview
Ausbiz interviews the CEO of Medlab, Sean Hall about the future of Medlab
2020-12-02
Nanabis Presentation
Learn more about NanaBis and the significant opportunity ahead
2020-09-01
StockPal Webinar
In this part two of a four-part webinar recap, Sean Hall, Chief Executive Officer and Managing Director of Medlab (ASX:MDC) presented on the company’s latest announcements and updates while answering some questions during the Q&A session at the end.
2020-08-11
Page No.
